Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide Efficacy in Ataxia in PMM2-CDG
NCT04679389Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acetazolamide in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), sponsored by Mayo Clinic. Started Mar 2021; status: terminated.
02
Drugs
acetazolamide
03
Conditions
phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)
Beyond the preview
Go deeper on NCT04679389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679389.